What Molecular Response Means in Myeloid Leukemia and How Often It Is Measured

Key Takeaways
- Molecular response measures BCR-ABL1 transcripts in blood by quantitative PCR and can detect roughly one leukemia cell among 100,000 at its deepest reported level, far beyond what a microscope-based marrow test can see.
- Major molecular response means BCR-ABL1 at or below 0.1% on the International Scale, a thousandfold fall from the standardized baseline, and is the level at which progression risk becomes very small in guideline-cited studies.
- European LeukemiaNet 2020 milestones are 10% or lower at three months, 1% or lower at six months and 0.1% or lower at twelve months, with later attainment classed as a warning rather than a failure.
- Testing is typically every three months until a stable major molecular response, then every three to six months, and monthly for the first six months if treatment is paused under supervision.
- The assay varies by about half a log between runs, so a shift from 0.05% to 0.12% may reflect the same disease burden and is confirmed on a repeat sample before any decision.
- An undetectable result means below that run's detection limit, not zero disease, which is why laboratories report the sensitivity reached alongside it.
In chronic myeloid leukemia, molecular response describes how far the level of BCR-ABL1, the abnormal gene that drives the disease, has fallen in the blood. It is measured with a quantitative PCR test and reported on the International Scale. Guidelines typically recommend testing every three months until a stable major molecular response is reached, then every three to six months, with monthly checks if treatment is paused under supervision.
The parking garage is where a lot of people read their results. Phone propped on the steering wheel, patient portal open, a line that says BCR-ABL1 (IS): 0.032%. Is that good? It was 0.02% last time. Nobody in the building above had time to explain what the decimal meant, and the next appointment is weeks away.
If you or someone you love has chronic myeloid leukemia, this scene will feel familiar, because CML molecular response monitoring is the thread that runs through the entire course of the disease. A blood sample every few months becomes the closest thing to a scorecard most people will ever have for a cancer, and learning to read it is part of living with the condition.
This article walks through what the test detects, why the results look the way they do, how often guidelines suggest repeating it, and where the common misreadings hide. The aim is not to turn you into your own hematologist, but to help you walk into the next conversation knowing which questions matter.
What does molecular response mean in CML?
Chronic myeloid leukemia, or CML, is a slow-growing cancer of the blood-forming cells in the bone marrow. Almost every case traces back to a single accident: a piece of chromosome 9 swaps places with a piece of chromosome 22, producing the shortened chromosome 22 known as the Philadelphia chromosome. The swap fuses two genes, BCR and ABL1, into one abnormal gene, BCR-ABL1, which makes a tyrosine kinase, an enzyme that behaves like an accelerator pedal stuck to the floor, telling white blood cells to keep dividing.
Doctors describe how well treatment is working in three layers. Hematologic response means blood counts have returned to the normal range. Cytogenetic response means the Philadelphia chromosome can no longer be seen when marrow cells are examined under a microscope. Molecular response goes deeper still: it measures how much BCR-ABL1 genetic material, called transcript, is circulating in the blood. Because each layer is more sensitive than the one before, a person can have entirely normal blood counts and still carry a measurable amount of BCR-ABL1.
That sensitivity is the whole point. The microscope-based cytogenetic test examines roughly 20 cells at a time, so it cannot see disease below about one Philadelphia-positive cell in 20. The molecular test can register one BCR-ABL1-carrying cell among tens of thousands of normal ones, and at its deepest reported level, one in about 100,000, according to the response definitions in the European LeukemiaNet 2020 recommendations. Molecular response has therefore become the main language of CML follow-up: it is the number your hematologist quotes, the number that decides whether treatment is on track, and, for some people years down the line, the number that opens a conversation about pausing therapy under supervision.
How the BCR-ABL PCR test actually works
The test behind all of this is a quantitative reverse-transcription polymerase chain reaction, usually shortened to RT-qPCR or simply the BCR-ABL PCR test. PCR is a laboratory method that copies a specific stretch of genetic material over and over until there is enough to measure. For the patient, it begins with an ordinary blood draw; bone marrow is not usually needed for routine molecular monitoring, as MedlinePlus explains.

In the laboratory, technicians extract RNA, the working copies that cells make from their genes, from the white blood cells in the sample. An enzyme converts that RNA into a more stable form called cDNA. Then the amplification begins. Short primer sequences designed to match only the BCR-ABL1 fusion junction latch on wherever the abnormal gene is present, and a fluorescent signal builds with each copying cycle. The earlier the fluorescence crosses a threshold, the more BCR-ABL1 was in the tube to start with.
A raw count on its own would be meaningless, because a small sample or degraded RNA would look falsely reassuring. So the same run also measures a control gene present in every cell, most commonly ABL1 itself or GUSB. The result you eventually see is a ratio: BCR-ABL1 copies divided by control gene copies, expressed as a percentage. If too few control copies were amplified, the run is flagged as insufficiently sensitive and repeated.
Two practical points follow. The sample has to reach the laboratory quickly, because RNA breaks down within hours at room temperature, which is why tubes are labeled with a draw time and sent promptly. And the test is designed for the common transcript types; people with rarer BCR-ABL1 variants may need a customized assay, a point covered later.
Why results are reported on the International Scale
Early molecular results were notoriously hard to compare. One center might report a 2,000-fold reduction from its own pooled baseline, another 0.05% against a different control gene. To fix this, laboratories worldwide agreed to convert their numbers onto a shared International Scale, abbreviated IS. On this scale, 100% represents the average BCR-ABL1 level in untreated patients at diagnosis, and every reduction is expressed as a percentage of that starting point. Each accredited laboratory carries its own conversion factor, derived from shared reference samples, so 0.1% in one country means the same disease burden as 0.1% in another.
Because the numbers span several orders of magnitude, clinicians often speak in logs rather than percentages. A one-log reduction is a tenfold fall; three logs is a thousandfold fall. The table sets out the labels used in the European LeukemiaNet 2020 recommendations.
| Response label | BCR-ABL1 on the International Scale | Fall from standardized baseline |
|---|---|---|
| Early molecular response | 10% or lower | At least 1 log (tenfold) |
| Roughly equivalent to complete cytogenetic response | 1% or lower | At least 2 logs (hundredfold) |
| Major molecular response (MMR, MR3) | 0.1% or lower | At least 3 logs (thousandfold) |
| Deep molecular response, MR4 | 0.01% or lower | At least 4 logs |
| Deep molecular response, MR4.5 | 0.0032% or lower | At least 4.5 logs |
| Deep molecular response, MR5 | 0.001% or lower | At least 5 logs |
One more label matters: undetectable. A report of undetectable BCR-ABL1 does not mean zero disease; it means the amount was below what that particular run could measure. Good laboratories therefore state the sensitivity achieved alongside an undetectable result, for example undetectable at MR4.5 sensitivity. The sensitivity figure, not the word itself, carries the clinical meaning.
What counts as a major molecular response in CML, and why 0.1% matters
Of all the thresholds in the table, one has earned a special place: 0.1% on the International Scale, known as major molecular response or MMR. In clinic language, reaching MMR is often described as a safe harbor, and the reason is straightforward. In the long-term studies summarized by the European LeukemiaNet, people who reached and held MMR very rarely saw their disease progress to the more aggressive accelerated or blast phases. Progression is what CML treatment is really trying to prevent, and MMR is the level at which that risk becomes very small.

MMR is therefore the target most people are steered toward in the first year of treatment. The European LeukemiaNet 2020 recommendations frame the journey as milestones: BCR-ABL1 at or below 10% by three months, at or below 1% by six months, and at or below 0.1% by twelve months, each described as the optimal result at that timepoint. Reaching those markers a little later is not a failure; it places a person in a warning category that prompts closer monitoring rather than an automatic change in treatment.
What about going deeper than MMR? Levels of 0.01% or below are grouped as deep molecular response, abbreviated DMR. The evidence reviewed by the same guideline suggests that moving from MMR to DMR does not further reduce the risk of progression. Its value lies elsewhere: a stable deep response sustained for several years is the entry ticket to a supervised attempt at stopping medication, discussed later. Hematologists sometimes put it this way: MMR is about safety; DMR is about options. Neither is a promise, and neither replaces the judgment of the treating team.
How often is BCR-ABL tested? A typical CML molecular response monitoring schedule
The schedule people most often ask about is refreshingly consistent across major guidelines. The European LeukemiaNet 2020 recommendations advise a BCR-ABL1 PCR test at diagnosis to establish the transcript type, then every three months after treatment begins until major molecular response has been reached and confirmed. Once MMR is stable, testing can stretch to every three to six months. Cleveland Clinic describes the same rhythm in patient terms: regular blood tests, more frequent early on, then less often as results stay steady.
Three months is not an arbitrary interval. It matches the timepoints at which milestones are judged, and it is long enough for a genuine trend to show through the normal wobble of the test. Two results a few weeks apart tell you very little; two results a quarter apart begin to trace a line.
The frequency tightens in specific circumstances. A warning result, such as BCR-ABL1 above 10% at three months, prompts a repeat within one to three months rather than waiting a full quarter, so the team can distinguish a slow starter from a real problem. A rise of more than about one log, particularly one that pushes a person out of MMR, is usually confirmed on a second sample within four to six weeks before any decision is made. After a treatment change, the three-month clock restarts. During a supervised stop of medication, monitoring becomes monthly for the first six months, a schedule covered in its own section below.
Alongside PCR, a complete blood count is checked at every visit. A bone marrow test with cytogenetics, the microscope-based chromosome analysis, is reserved for diagnosis, for treatment failure, or for the rare cases where the transcript cannot be measured by standard PCR. For most people in stable response, follow-up is a blood draw and a conversation, nothing more invasive.
Who needs this kind of monitoring, and who is usually asked to wait
Everyone diagnosed with CML and treated with a tyrosine kinase inhibitor, the class of oral medicines that blocks the BCR-ABL1 enzyme, is monitored molecularly. There is no version of modern CML care that skips it. Age, other health conditions and which specific medicine is prescribed do not change the need for the test, only sometimes its interpretation.
Being asked to wait, in this context, usually means being asked not to act on a single number. Several groups hear this often.
- People whose first result after starting treatment sits above the 10% mark. The guideline response is a repeat test, not an immediate switch, because some people simply take longer to respond, and a confirmed result at the next timepoint carries far more weight.
- People who have just dipped out of MMR by a small margin, say from 0.08% to 0.15%. A shift of this size sits within the measurement variability of the assay, and confirmation on a fresh sample is standard before anything changes.
- People in deep response who are keen to stop medication but have not yet met the duration criteria. The European LeukemiaNet 2020 recommendations set minimum requirements of at least five years of treatment and at least two years of documented deep molecular response before a stop is considered, with longer periods described as preferable.
A different kind of waiting applies to people whose disease produces a rare, atypical BCR-ABL1 transcript that standard assays cannot quantify. They may be followed by cytogenetics or a laboratory-specific test while a suitable method is arranged. In the accelerated or blast phases, where the disease behaves more aggressively, molecular numbers are read alongside marrow findings and blood counts rather than as the sole guide. In every case, the pace of monitoring is set by the treating team, never by the calendar alone.
What the weeks around a molecular test usually look like
For someone in stable response, a monitoring cycle has a familiar shape. It starts with a blood draw, often combined with the routine complete blood count and, depending on the medicine, checks of liver, kidney or heart-related markers. Nothing special is needed beforehand: no fasting, no change to medication timing. The one thing worth mentioning to the phlebotomist is anything that might delay transport, since the RNA in the sample degrades if the tube sits too long.
Then comes the wait. Quantitative PCR is a batched, specialist test, so results take longer than a standard blood count; turnaround depends on the laboratory, and it is worth asking your team what is typical for yours so that a delay does not read as bad news. Many people describe this interval as the hardest part of the cycle. Planning something ordinary for those days, and agreeing in advance how the result will be communicated, whether by phone, portal or at the next visit, takes some of the edge off.
The result arrives as a percentage on the International Scale, sometimes with a log value and, if the laboratory is doing its job, the sensitivity of the run. Your hematologist reads it in context: where it sits against the last two or three results, how long you have been on treatment, and whether missed medication days or an intercurrent illness might explain a blip. If the number is steady or falling, the next test is booked three to six months out. If it has risen, the next step is almost always a repeat sample within weeks, not an immediate change. Only when a rise is confirmed does the conversation about adherence, side effects, mutation testing or a different medicine begin.
What a rise in BCR-ABL means, and when it actually matters
A number that goes up is frightening, and it is also common. Small rises are part of the biology and the measurement. The assay has an inherent variability of roughly half a log, so 0.05% and 0.12% may reflect the same disease burden on different days. Fluctuation within the MMR range, or slightly above and then back below it, is a pattern many long-term patients recognize.
Guidelines therefore build in confirmation. In the European LeukemiaNet 2020 framework, a rise becomes clinically significant when it is confirmed on a second sample and crosses a meaningful threshold: BCR-ABL1 climbing above 0.1% (loss of MMR) is a warning if it stays at or below 1%, and above 1% is defined as treatment failure at any time after twelve months. A single value that jumps more than one log also earns an early repeat even if it stays within a response category.
When a rise is real, the first question is almost always about the medicine itself. Tyrosine kinase inhibitors only work while they are being taken, and patient guidance from the NHS and others links missed days to lost response. Interactions with other drugs or supplements that affect how the liver processes medicines can have the same effect, which is why your team asks about every new prescription and over-the-counter product.
The second question is whether the leukemia cells have changed. A kinase domain mutation is a small alteration in the BCR-ABL1 gene that changes the shape of the enzyme so a particular inhibitor no longer fits. Mutation analysis, a separate sequencing test on the same kind of blood sample, is recommended after confirmed failure or a concerning warning, and its result helps the team choose among inhibitors. That choice, and its timing, rests with the prescribing clinician.
Molecular monitoring and treatment-free remission in CML
Treatment-free remission, or TFR, describes stopping a tyrosine kinase inhibitor under close supervision while the disease stays at an undetectable or very low level. It is the clearest example of why molecular monitoring matters beyond the first year, because the entire strategy depends on detecting a returning signal early enough to restart treatment safely.
The European LeukemiaNet 2020 recommendations describe who may be considered: people in the chronic phase from diagnosis, with a common transcript type that standard PCR can measure, who have taken a TKI for at least five years and have held a deep molecular response (MR4 or better) for at least two years, with longer durations described as optimal. Access to a laboratory that can deliver rapid, sensitive results is listed as a requirement, not a nicety.
The monitoring schedule after stopping is the most intensive in CML care. The same guideline advises a PCR test every month for the first six months, every two months from months seven to twelve, and every three months thereafter for as long as the person remains off treatment. The trigger for restarting is loss of MMR, a confirmed rise above 0.1%.
What does the evidence show? In the trials the guideline reviewed, roughly 40–60% of carefully selected people remained in remission after stopping; the remainder saw BCR-ABL1 rise, most within the first six months, and the great majority regained their previous response after restarting. Some people who stop also experience a temporary withdrawal syndrome of joint or muscle aches. None of this is a promise for any individual, and no one should pause or stop a TKI on their own. It is a shared decision, made with a team that has the monitoring in place to catch a return early.
Why one number is never the whole story
People understandably fixate on the latest percentage, but hematologists read three things around it.
The first is the trend. A result of 0.2% means something different in a person whose previous values were 0.9% and 0.4% (falling steadily, on track) than in one whose values were 0.01% and 0.05% (rising through two consecutive tests). Guidelines are explicit that direction and confirmation matter more than any isolated value.
The second is the laboratory. Although the International Scale aligns results between centers, it does not eliminate all variation, and results from two different laboratories are not interchangeable to the decimal. Switching laboratories mid-course, for instance after a move, is a recognized reason for an unexplained shift, and teams usually want one or two results from the new laboratory before drawing conclusions. The sensitivity of each run also varies with sample quality, which is why an undetectable result on a poor sample may be less reassuring than a detectable 0.005% on a good one.
The third is the person. Missed medication days, a new prescription that interferes with metabolism, a recent infection, or a bout of vomiting that prevented pills from being absorbed can each nudge the number. Side effects that make the medicine hard to take are a legitimate part of this conversation, and raising them is not a failing. Complete blood counts, spleen size on examination and, where needed, marrow findings round out the picture.
Put simply, molecular monitoring is a conversation carried out in numbers. The value on the report is the opening line; what your team does with it depends on everything that surrounds it.
What people often get wrong about CML molecular response monitoring
Myths gather quickly around any test with decimals in it. A few deserve direct correction.
“Undetectable means gone.” It means below the detection limit of that run. Research methods more sensitive than routine PCR have found residual BCR-ABL1 in many people whose standard tests are undetectable, and treatment-free remission data show that disease can return after years of undetectable results. Undetectable is excellent news, not an ending.
“Any rise means the medicine has stopped working.” Most small rises reflect assay variability, missed days or a temporary illness, and guidelines require confirmation before anything is labeled a failure. A single number is a prompt for a repeat, not a verdict.
“Reaching a deep response means I can stop my medicine.” Deep response is one criterion among several, including years of treatment, transcript type, disease phase and access to rapid monitoring, and even then stopping is a supervised trial with a restart plan, never a personal decision.
“Feeling well means the numbers must be fine.” Chronic-phase CML often causes no symptoms at all, which is exactly why molecular testing exists. Rising BCR-ABL1 is silent until it is not.
“Results from different laboratories compare to the decimal.” The International Scale narrows the gap but does not close it; a change in laboratory can produce a shift that has nothing to do with the disease.
“Deeper is always better.” The evidence summarized by the European LeukemiaNet does not show a lower risk of progression below MMR. Deeper responses widen future options; they do not make a person who is stable at MMR less safe.
Each of these misunderstandings produces either unnecessary panic or unwarranted relaxation. Knowing the shape of the evidence protects against both.
Living with the rhythm of a lifelong blood test
Few conditions ask people to build their year around a percentage. Many CML patients describe PCR anxiety, the low hum that starts a week before the draw and peaks in the days before the result. The experience is common enough that hematology nurses often raise it unprompted.
A few habits, drawn from what long-term patients and clinicians describe, tend to help. Keeping your own simple record of dates and values, with the laboratory’s sensitivity noted, turns a stream of isolated numbers into a line you can see. Asking your team to explain results in logs as well as percentages makes small fluctuations feel proportionate: a move from 0.02% to 0.04% is a doubling in percentage terms but only a third of a log, well within normal variation. Agreeing in advance what would and would not prompt a change in plan removes the temptation to interpret every decimal alone at midnight.
Taking the medicine as prescribed is the single factor most within a person’s control, and it is harder than it sounds over years of daily pills, particularly when side effects wear you down. Telling your team honestly about missed days is not an admission of failure; it is clinically useful information that can spare an unnecessary change of treatment. Support groups, in person or online, are where many people first learn that a warning result usually resolves, and hearing it from someone who has lived it carries a weight no leaflet can match.
Above all, the monitoring exists because CML is, for most people, a condition that can be controlled for a very long time. The test is the mechanism of that control, not a recurring exam to be passed or failed.
Questions to ask your care team
Good monitoring depends on a shared understanding of what the numbers mean for you. These questions are a starting point for that conversation; write down the answers, because they change over time.
- What transcript type do I have, and can the standard PCR test measure it reliably?
- Which laboratory runs my test, is it aligned to the International Scale, and what sensitivity does it usually reach?
- What was my result today in percentage and in logs, and how does it compare with my last three results?
- Which milestone are we aiming for at my current stage of treatment, and when is the next one judged?
- How often will I be tested from here, and what would make you test sooner?
- If my number rises, what size of change would prompt a repeat, and what size would prompt a discussion about changing treatment?
- Would you test for kinase domain mutations if my response slipped, and what would that involve?
- Are any of my other medicines, supplements or foods likely to interfere with how my treatment is absorbed or processed?
- How will my results be communicated, and who do I call if I have not heard within the expected time?
- Am I someone for whom a supervised treatment pause might eventually be considered, and what criteria would I need to meet first?
- If I move or change hospitals, how do we keep the monitoring on schedule and the results comparable?
None of these questions has a universal answer, which is precisely why they are worth asking. The team that knows your history, your transcript and your laboratory is the only one that can give you the answer that applies to you.
When to call your doctor
Molecular monitoring is designed to catch problems before symptoms appear, but it is not the only safety net, and no scheduled test should stop you from calling between appointments. Contact your hematology team promptly if you notice any of the following, which the NHS and Mayo Clinic list among features of CML that is not well controlled or of treatment complications:
- A fever, chills or an infection that is not settling, especially if you have been told your white cell count is low.
- Unexplained bruising, bleeding gums, nosebleeds that are hard to stop, or blood in urine or stool.
- Drenching night sweats, unintended weight loss, or a return of profound tiredness after a period of feeling well.
- Fullness, discomfort or a firm swelling under the left ribs, which can signal an enlarging spleen.
- New bone pain, or shortness of breath and chest tightness at rest or on mild exertion.
- Persistent vomiting or diarrhea that stops you keeping your medicine down, or a stretch of missed days for any reason.
- Yellowing of the skin or eyes, sudden swelling of the legs or face, a rapid or irregular heartbeat, or a severe rash, all of which may relate to the medicine rather than the disease.
Seek emergency care for chest pain, sudden severe breathlessness, signs of stroke such as facial drooping or one-sided weakness, or bleeding that will not stop. These are uncommon, but they are not situations to wait out until the next result.
Two quieter reasons to call also matter. If your scheduled PCR result has not arrived within the time your team said to expect, ask. And if a result has landed in your portal without explanation and you are worried, request a conversation rather than searching for an interpretation elsewhere. Your team would far rather hear about a small concern early than a large one late.
Frequently asked questions
What is the BCR-ABL PCR test looking for?
It looks for RNA copies of the BCR-ABL1 fusion gene, the abnormal gene created by the Philadelphia chromosome that drives chronic myeloid leukemia. The laboratory amplifies that sequence from white blood cells, compares it with a control gene present in every cell, and reports the ratio as a percentage on the International Scale. The lower the percentage, the less leukemia remains detectable, according to MedlinePlus.
What is a major molecular response in CML?
Major molecular response, or MMR, means BCR-ABL1 has fallen to 0.1% or lower on the International Scale, a thousandfold reduction from the standardized starting level. The European LeukemiaNet 2020 recommendations list it as the optimal result by twelve months of treatment. People who reach and hold MMR very rarely progress to advanced phases, which is why clinicians treat it as the key safety milestone.
How often is BCR-ABL tested after a CML diagnosis?
Guidelines advise testing at diagnosis, then every three months until major molecular response is reached and confirmed, after which the interval can lengthen to every three to six months. Testing becomes more frequent after a warning result, after a change of medicine, or during a supervised treatment pause, when it is monthly for the first six months. Your team sets the exact schedule based on your results.
Can molecular monitoring lead to treatment-free remission in CML?
For some people, yes, but only under strict conditions. The European LeukemiaNet 2020 recommendations describe minimum criteria of at least five years of TKI treatment and at least two years of sustained deep molecular response, plus access to rapid, sensitive PCR testing. Roughly 40–60% of carefully selected people in the reviewed trials stayed in remission after stopping; the rest restarted treatment when their numbers rose. It is a shared decision, never a self-directed one.
Does an undetectable BCR-ABL result mean the leukemia is gone?
No. Undetectable means the amount of BCR-ABL1 was below what that particular test run could measure, which is why laboratories report the sensitivity alongside it. More sensitive research methods often still find traces, and disease can return after years of undetectable results. It is very good news and a sign of excellent control, but monitoring continues because the biology is not fully eliminated.
Why did my BCR-ABL number go up if I take my medicine every day?
Small rises are usually measurement variability. The assay varies by roughly half a log between runs, so a move from 0.02% to 0.05% can occur with no real change in disease. Recent infections, sample quality and a change of laboratory can also shift results. Guidelines call for a repeat sample before any rise is treated as meaningful, and only confirmed rises above set thresholds prompt further action.
Do I need a bone marrow test for molecular monitoring?
Usually not. Routine molecular monitoring uses an ordinary blood sample, because BCR-ABL1 transcripts in blood track closely with those in marrow. A bone marrow test with chromosome analysis is generally reserved for diagnosis, for confirmed treatment failure, for suspected progression to accelerated or blast phase, or for the uncommon situation where a person’s transcript type cannot be measured by standard PCR.
What does the International Scale mean on my report?
The International Scale, abbreviated IS, is a shared reference system that lets laboratories worldwide report BCR-ABL1 results in comparable units. On it, 100% represents the average level in untreated patients at diagnosis, and each laboratory applies a conversion factor derived from standard reference samples. A result of 0.1% IS therefore represents the same disease burden wherever it is measured, though small between-laboratory differences remain.
What happens if I miss a guideline milestone?
Missing a milestone usually places you in a warning category rather than a failure category. For example, BCR-ABL1 above 10% at three months prompts a repeat within one to three months and a review of adherence and interactions, not an automatic switch. Only confirmed results that cross failure thresholds, such as above 10% at six months or above 1% after twelve months, lead to discussions about mutation testing and alternative medicines.
Can I compare my results with another patient's?
Only loosely. Even on the International Scale, different laboratories, sample qualities and transcript types produce results that are not interchangeable to the decimal. More importantly, what matters clinically is your own trend over time, your stage of treatment and your milestones, not someone else’s number. Support groups are valuable for shared experience, but interpretation of any specific result belongs with your own treating team.
References
- MedlinePlus: BCR-ABL Genetic Test
- NHS: Chronic myeloid leukaemia
- MedlinePlus Medical Encyclopedia: Chronic myelogenous leukemia (CML)
This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.
More from the Blog
Bleeding, Breathing Changes or Fever After Head Cancer Treatment: When to Call Your Team
After head and neck cancer treatment, call your care team the same day for any fever at or above the threshold they gave you…
Is a Second Pathology Review Useful for Lymphoma? Why Subtype Accuracy Matters
A second pathology review of a lymphoma biopsy is widely considered worthwhile, especially before treatment begins. Lymphoma has dozens of subtypes that can look…
Preparing for HIPEC: Bowel Preparation, Fasting and the Medication Review Before Surgery
Preparing for HIPEC usually begins several weeks before surgery and centers on three tasks: a structured medication review covering blood thinners, diabetes medicines and…
What the Pathology Report Says After Basal Cell Carcinoma Removal and Why Margins Matter
After basal cell carcinoma removal, the pathology report confirms the diagnosis, names the growth pattern (subtype), and states whether cancer cells reach the cut…
Can a Second Opinion Change a Pancreatic Cancer Plan? When Surgical Review Is Requested
A second opinion can change a pancreatic cancer plan, though it more often confirms one. A surgical review re-reads the scans to judge whether…
What a Neck Dissection Removes and How the Neck Heals After Surgery
A neck dissection removes lymph nodes, and the fatty tissue around them, from defined zones of the neck so a pathologist can check whether…






